CN101518532A - 用于呼吸道疾病治疗的抗胆碱能药和4型磷酸二酯酶抑制剂的组合 - Google Patents
用于呼吸道疾病治疗的抗胆碱能药和4型磷酸二酯酶抑制剂的组合 Download PDFInfo
- Publication number
- CN101518532A CN101518532A CN200910133531A CN200910133531A CN101518532A CN 101518532 A CN101518532 A CN 101518532A CN 200910133531 A CN200910133531 A CN 200910133531A CN 200910133531 A CN200910133531 A CN 200910133531A CN 101518532 A CN101518532 A CN 101518532A
- Authority
- CN
- China
- Prior art keywords
- glycopyrronium bromide
- asthma
- daily dose
- pde4 inhibitor
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title claims abstract description 26
- 208000023504 respiratory system disease Diseases 0.000 title claims abstract description 5
- 238000011282 treatment Methods 0.000 title claims description 21
- 239000000812 cholinergic antagonist Substances 0.000 title description 2
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 title 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims abstract description 38
- 208000006673 asthma Diseases 0.000 claims abstract description 33
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims abstract description 25
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229960002586 roflumilast Drugs 0.000 claims abstract description 8
- 230000000699 topical effect Effects 0.000 claims abstract description 3
- 239000003814 drug Substances 0.000 claims description 29
- 229960002462 glycopyrronium bromide Drugs 0.000 claims description 26
- 229940079593 drug Drugs 0.000 claims description 14
- 241000283073 Equus caballus Species 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 6
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000003380 propellant Substances 0.000 claims description 2
- 239000013066 combination product Substances 0.000 claims 5
- 229940127555 combination product Drugs 0.000 claims 5
- 241000124008 Mammalia Species 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- 230000001078 anti-cholinergic effect Effects 0.000 abstract description 19
- 239000000203 mixture Substances 0.000 abstract description 11
- 230000004054 inflammatory process Effects 0.000 abstract description 9
- DPHDSIQHVGSITN-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-2-[1-[(4-fluorophenyl)methyl]-5-hydroxyindol-3-yl]-2-oxoacetamide Chemical compound C1=C(C(=O)C(=O)NC=2C(=CN=CC=2Cl)Cl)C2=CC(O)=CC=C2N1CC1=CC=C(F)C=C1 DPHDSIQHVGSITN-UHFFFAOYSA-N 0.000 abstract description 8
- 206010061218 Inflammation Diseases 0.000 abstract description 7
- 229940124630 bronchodilator Drugs 0.000 abstract description 7
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 abstract description 4
- 239000000168 bronchodilator agent Substances 0.000 abstract description 3
- 229940015042 glycopyrrolate Drugs 0.000 abstract description 2
- 238000011321 prophylaxis Methods 0.000 abstract description 2
- 238000009472 formulation Methods 0.000 abstract 1
- 238000002636 symptomatic treatment Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- VPNYRYCIDCJBOM-UHFFFAOYSA-M Glycopyrronium bromide Chemical compound [Br-].C1[N+](C)(C)CCC1OC(=O)C(O)(C=1C=CC=CC=1)C1CCCC1 VPNYRYCIDCJBOM-UHFFFAOYSA-M 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 208000037883 airway inflammation Diseases 0.000 description 7
- 102100039705 Beta-2 adrenergic receptor Human genes 0.000 description 6
- 239000000048 adrenergic agonist Substances 0.000 description 6
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 6
- 108010014499 beta-2 Adrenergic Receptors Proteins 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 210000000440 neutrophil Anatomy 0.000 description 6
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 6
- 101100296720 Dictyostelium discoideum Pde4 gene Proteins 0.000 description 5
- 101100082610 Plasmodium falciparum (isolate 3D7) PDEdelta gene Proteins 0.000 description 5
- 230000005923 long-lasting effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- LERNTVKEWCAPOY-DZZGSBJMSA-N tiotropium Chemical compound O([C@H]1C[C@@H]2[N+]([C@H](C1)[C@@H]1[C@H]2O1)(C)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 LERNTVKEWCAPOY-DZZGSBJMSA-N 0.000 description 5
- 229940110309 tiotropium Drugs 0.000 description 5
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 4
- 210000000038 chest Anatomy 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 3
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003246 corticosteroid Substances 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000000222 eosinocyte Anatomy 0.000 description 3
- 239000003862 glucocorticoid Substances 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 3
- 229960001888 ipratropium Drugs 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000009325 pulmonary function Effects 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000000391 smoking effect Effects 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 208000018569 Respiratory Tract disease Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000001022 anti-muscarinic effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000023819 chronic asthma Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 210000004969 inflammatory cell Anatomy 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 239000003149 muscarinic antagonist Substances 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 2
- 229950005741 rolipram Drugs 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- LSLYOANBFKQKPT-DIFFPNOSSA-N 5-[(1r)-1-hydroxy-2-[[(2r)-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]benzene-1,3-diol Chemical compound C([C@@H](C)NC[C@H](O)C=1C=C(O)C=C(O)C=1)C1=CC=C(O)C=C1 LSLYOANBFKQKPT-DIFFPNOSSA-N 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010014950 Eosinophilia Diseases 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000201295 Euphrasia Species 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 108010002616 Interleukin-5 Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 206010028665 Myxoedema Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000002164 acetylcholinergic effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000036428 airway hyperreactivity Effects 0.000 description 1
- 210000005091 airway smooth muscle Anatomy 0.000 description 1
- 210000005057 airway smooth muscle cell Anatomy 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000003092 anti-cytokine Effects 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 229960004495 beclometasone Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 238000011685 brown norway rat Methods 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000008614 cellular interaction Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000005482 chemotactic factor Substances 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 229960001022 fenoterol Drugs 0.000 description 1
- 229960002848 formoterol Drugs 0.000 description 1
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 208000003786 myxedema Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000001129 nonadrenergic effect Effects 0.000 description 1
- 230000002536 noncholinergic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000009291 secondary effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013595 supernatant sample Substances 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54195504P | 2004-02-06 | 2004-02-06 | |
| US60/541,955 | 2004-02-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200580002345XA Division CN100512813C (zh) | 2004-02-06 | 2005-01-24 | 用于呼吸道疾病治疗的抗胆碱能药和4型磷酸二酯酶抑制剂的组合 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN101518532A true CN101518532A (zh) | 2009-09-02 |
Family
ID=34837532
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910133531A Pending CN101518532A (zh) | 2004-02-06 | 2005-01-24 | 用于呼吸道疾病治疗的抗胆碱能药和4型磷酸二酯酶抑制剂的组合 |
| CNB200580002345XA Expired - Fee Related CN100512813C (zh) | 2004-02-06 | 2005-01-24 | 用于呼吸道疾病治疗的抗胆碱能药和4型磷酸二酯酶抑制剂的组合 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB200580002345XA Expired - Fee Related CN100512813C (zh) | 2004-02-06 | 2005-01-24 | 用于呼吸道疾病治疗的抗胆碱能药和4型磷酸二酯酶抑制剂的组合 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20050175547A1 (https=) |
| EP (1) | EP1713471B1 (https=) |
| JP (1) | JP4700014B2 (https=) |
| CN (2) | CN101518532A (https=) |
| AT (1) | ATE541570T1 (https=) |
| AU (1) | AU2005210084B2 (https=) |
| CA (1) | CA2550848C (https=) |
| CY (1) | CY1112968T1 (https=) |
| DK (1) | DK1713471T3 (https=) |
| ES (1) | ES2381116T3 (https=) |
| HR (1) | HRP20120286T1 (https=) |
| NO (1) | NO337023B1 (https=) |
| NZ (1) | NZ548301A (https=) |
| PL (1) | PL1713471T3 (https=) |
| PT (1) | PT1713471E (https=) |
| RU (1) | RU2437658C2 (https=) |
| SI (1) | SI1713471T1 (https=) |
| WO (1) | WO2005074982A2 (https=) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110403922A (zh) * | 2013-01-28 | 2019-11-05 | 理森制药股份公司 | 通过吸入罗氟司特n-氧化物治疗自身免疫、呼吸和/或炎性病症的方法 |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| JP2007524699A (ja) * | 2004-02-27 | 2007-08-30 | アルタナ ファルマ アクチエンゲゼルシャフト | ロフルミラストとグリコピロニウムとの組合せ物 |
| ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| EP1616567A1 (en) * | 2004-07-16 | 2006-01-18 | Boehringer Ingelheim Pharma GmbH & Co.KG | Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts |
| AU2006305619A1 (en) * | 2005-10-19 | 2007-04-26 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of muscarinic receptor antagonists |
| EP1894568A1 (en) * | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
| KR20100072295A (ko) * | 2007-10-25 | 2010-06-30 | 머크 프로스트 캐나다 리미티드 | 병용 요법 |
| US20100055045A1 (en) | 2008-02-26 | 2010-03-04 | William Gerhart | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations |
| CA2716936C (en) * | 2008-02-26 | 2018-06-05 | Elevation Pharmaceuticals, Inc. | Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
| EP2968312B1 (en) * | 2013-03-15 | 2018-01-31 | Verona Pharma PLC | Drug combination |
| TW201542207A (zh) * | 2013-10-03 | 2015-11-16 | Otsuka Pharma Co Ltd | 嚴重氣喘治療劑 |
| CN104586841A (zh) * | 2013-10-30 | 2015-05-06 | 中国药科大学 | (3r,2’r)-格隆溴铵作为m3毒蕈碱性受体拮抗剂在制药中的用途 |
| CN104800192A (zh) * | 2014-01-27 | 2015-07-29 | 成都英诺新科技有限公司 | 一种罗氟司特吸入粉雾剂及制备方法 |
| RU2691110C2 (ru) * | 2017-11-20 | 2019-06-11 | Федеральное государственное бюджетное учреждение науки Сибирский федеральный научный центр агробиотехнологий Российской академии наук (СФНЦА РАН) | Препарат для лечения заболеваний дыхательных путей у лошадей и способ его применения |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE59410119D1 (de) * | 1993-07-02 | 2002-06-20 | Byk Gulden Lomberg Chem Fab | Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren |
| WO1998000016A1 (en) * | 1996-07-01 | 1998-01-08 | Sepracor, Inc. | Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate |
| US6384038B1 (en) | 1998-04-14 | 2002-05-07 | Sepracor Inc. | Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants |
| WO1999062720A1 (fr) * | 1998-05-29 | 1999-12-09 | Citizen Watch Co., Ltd. | Procede permettant de soumettre une imprimante a jet d'encre a un traitement de pre-utilisation |
| JP4672143B2 (ja) | 1998-08-04 | 2011-04-20 | ヤゴテック アーゲー | 医薬用エーロゾル製剤 |
| PL200941B1 (pl) | 1998-11-13 | 2009-02-27 | Jagotec Ag | Suchy proszkowy preparat inhalacyjny |
| DE19921693A1 (de) | 1999-05-12 | 2000-11-16 | Boehringer Ingelheim Pharma | Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika |
| US6086914A (en) | 1999-03-12 | 2000-07-11 | Weinstein; Robert E. | Nonsedating formulations for allergic rhinitis which possess antihistaminic and anticholinergic activity |
| US20040002548A1 (en) | 1999-05-12 | 2004-01-01 | Boehringer Ingelheim Pharma Kg | Medicament compositions containing anticholinergically-effective compounds and betamimetics |
| US20040028958A1 (en) | 2002-06-18 | 2004-02-12 | Total Innovative Manufacturing Llc | Recyclable fire-resistant moldable batt and panels formed therefrom |
| DE19961300A1 (de) | 1999-12-18 | 2001-06-21 | Asta Medica Ag | Vorratssystem für Arzneimittel in Pulverform und damit ausgestatteter Inhalator |
| DE10007203A1 (de) | 2000-02-17 | 2001-08-23 | Asta Medica Ag | Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis |
| GB0008660D0 (en) * | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
| GB0009583D0 (en) | 2000-04-18 | 2000-06-07 | Glaxo Group Ltd | Respiratory formulations |
| DE10110772A1 (de) * | 2001-03-07 | 2002-09-12 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren |
| GB0029903D0 (en) | 2000-12-07 | 2001-01-24 | Arakis Ltd | Use of anti-muscarinic agents |
| PT1372608E (pt) | 2001-03-30 | 2008-01-04 | Jagotec Ag | Formulações de aerossol médicas |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| IL158776A0 (en) * | 2001-05-25 | 2004-05-12 | Pfizer | A pde 4 inhibitor and an anti-cholinergic agent in combination for treating obstructive airways diseases |
| AU2002314102A1 (en) * | 2001-05-25 | 2002-12-09 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Combination of a pde4 inhibitor and tiotropium or derivate thereof for treating obstructive airways |
| GB0118373D0 (en) * | 2001-07-27 | 2001-09-19 | Glaxo Group Ltd | Novel therapeutic method |
| US7258118B2 (en) | 2002-01-24 | 2007-08-21 | Sofotec Gmbh & Co, Kg | Pharmaceutical powder cartridge, and inhaler equipped with same |
| DE10230769A1 (de) * | 2002-07-09 | 2004-01-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Arzneimittelkompositionen auf der Basis neuer Anticholinergika und PDE-IV-Inhibitoren |
| US20040038958A1 (en) * | 2002-07-11 | 2004-02-26 | Chris Rundfeldt | Topical treatment of skin diseases |
| UA82323C2 (uk) | 2002-08-09 | 2008-04-10 | Меда Фарма Гмбх & Ко. Кг | Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань |
| WO2004023984A2 (en) | 2002-09-13 | 2004-03-25 | Smith C Steven | Novel composition and method for treatment of upper respiratory conditions |
| CA2519682A1 (en) | 2003-03-28 | 2004-10-07 | Altana Pharma Ag | Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases |
| WO2004084896A1 (en) * | 2003-03-28 | 2004-10-07 | Altana Pharma Ag | Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases |
| JP2007530917A (ja) | 2003-07-11 | 2007-11-01 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | 改善された周波数決定 |
-
2005
- 2005-01-24 EP EP05701141A patent/EP1713471B1/en not_active Expired - Lifetime
- 2005-01-24 CN CN200910133531A patent/CN101518532A/zh active Pending
- 2005-01-24 ES ES05701141T patent/ES2381116T3/es not_active Expired - Lifetime
- 2005-01-24 DK DK05701141.3T patent/DK1713471T3/da active
- 2005-01-24 AT AT05701141T patent/ATE541570T1/de active
- 2005-01-24 JP JP2006551762A patent/JP4700014B2/ja not_active Expired - Fee Related
- 2005-01-24 CN CNB200580002345XA patent/CN100512813C/zh not_active Expired - Fee Related
- 2005-01-24 PT PT05701141T patent/PT1713471E/pt unknown
- 2005-01-24 WO PCT/EP2005/000651 patent/WO2005074982A2/en not_active Ceased
- 2005-01-24 AU AU2005210084A patent/AU2005210084B2/en not_active Ceased
- 2005-01-24 SI SI200531513T patent/SI1713471T1/sl unknown
- 2005-01-24 RU RU2006132040/15A patent/RU2437658C2/ru not_active Application Discontinuation
- 2005-01-24 PL PL05701141T patent/PL1713471T3/pl unknown
- 2005-01-24 NZ NZ548301A patent/NZ548301A/en not_active IP Right Cessation
- 2005-01-24 HR HR20120286T patent/HRP20120286T1/hr unknown
- 2005-01-24 CA CA2550848A patent/CA2550848C/en not_active Expired - Fee Related
- 2005-02-07 US US11/051,463 patent/US20050175547A1/en not_active Abandoned
-
2006
- 2006-07-13 US US11/485,486 patent/US20060251589A1/en not_active Abandoned
- 2006-08-31 NO NO20063880A patent/NO337023B1/no not_active IP Right Cessation
-
2009
- 2009-02-03 US US12/365,003 patent/US8097605B2/en not_active Expired - Lifetime
-
2012
- 2012-03-29 CY CY20121100323T patent/CY1112968T1/el unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110403922A (zh) * | 2013-01-28 | 2019-11-05 | 理森制药股份公司 | 通过吸入罗氟司特n-氧化物治疗自身免疫、呼吸和/或炎性病症的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100512813C (zh) | 2009-07-15 |
| PT1713471E (pt) | 2012-04-10 |
| JP2007520507A (ja) | 2007-07-26 |
| ATE541570T1 (de) | 2012-02-15 |
| NO20063880L (no) | 2006-11-02 |
| DK1713471T3 (da) | 2012-05-14 |
| AU2005210084B2 (en) | 2010-06-24 |
| US8097605B2 (en) | 2012-01-17 |
| EP1713471A2 (en) | 2006-10-25 |
| ES2381116T3 (es) | 2012-05-23 |
| CY1112968T1 (el) | 2016-04-13 |
| HK1096311A1 (zh) | 2007-06-01 |
| NO337023B1 (no) | 2015-12-28 |
| SI1713471T1 (sl) | 2012-07-31 |
| WO2005074982A2 (en) | 2005-08-18 |
| JP4700014B2 (ja) | 2011-06-15 |
| WO2005074982A3 (en) | 2006-04-06 |
| NZ548301A (en) | 2010-07-30 |
| EP1713471B1 (en) | 2012-01-18 |
| US20050175547A1 (en) | 2005-08-11 |
| US20060251589A1 (en) | 2006-11-09 |
| RU2006132040A (ru) | 2008-03-20 |
| CA2550848A1 (en) | 2005-08-18 |
| HRP20120286T1 (hr) | 2012-04-30 |
| CN1909899A (zh) | 2007-02-07 |
| US20090136429A1 (en) | 2009-05-28 |
| PL1713471T3 (pl) | 2012-06-29 |
| RU2437658C2 (ru) | 2011-12-27 |
| AU2005210084A1 (en) | 2005-08-18 |
| CA2550848C (en) | 2013-02-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101518532A (zh) | 用于呼吸道疾病治疗的抗胆碱能药和4型磷酸二酯酶抑制剂的组合 | |
| CN101321539B (zh) | 用于治疗炎性疾病的抗胆碱能药、糖皮质激素、β2-激动剂、PDE4抑制剂和抗白细胞三烯药的组合 | |
| RU2440813C2 (ru) | Комбинация (варианты) и фармацевтический препарат для лечения заболеваний дыхательных путей | |
| US20120039884A1 (en) | Compositions and methods for treating cardiovascular disease | |
| Bereda | Bronchial asthma: etiology, pathophysiology, diagnosis and management | |
| JP4991693B2 (ja) | 呼吸器疾患の治療のための抗コリン作用薬及びロイコトリエン受容体アンタゴニストの組み合わせ剤 | |
| JP2005501023A (ja) | Ｐｄｅ−４阻害剤およびｈ１受容体アンタゴニストを含んでなる組成物、および呼吸器疾患の治療のための医薬の製造におけるその使用 | |
| EP1429843B1 (en) | Combination of a pde inhibitor and a leukotriene receptor antagonist | |
| JP7588773B2 (ja) | グルタミン酸２ｂ受容体拮抗薬及びシグマ受容体作動薬の鎮咳薬としての使用 | |
| Durham | Tiotropium (Spiriva): a once-daily inhaled anticholinergic medication for chronic obstructive pulmonary disease | |
| CN103816155A (zh) | 一种包含茚达特罗和罗氟司特的药物组合产品 | |
| CN101829154B (zh) | 防治哮喘的药物组合物的制备方法 | |
| HK1136487A (en) | Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases | |
| HK1096311B (en) | Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases | |
| MXPA06008937A (en) | Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases | |
| Barkakaty | A Comparative Study of the Efficacy and Tolerability of Glycopyrronium-Formoterol Versus Tiotropium-Formoterol in Moderate Chronic Obstructive Pulmonary Disease | |
| Lung et al. | Medications in the allergy/asthma office | |
| HK1098356B (en) | The combination of anticholinergics and glucocorticoids for the long-term treatment of asthma and copd | |
| JPWO2004087151A1 (ja) | 医薬組成物 | |
| CN106466322A (zh) | 一种以布地奈德和噻托溴铵为活性成分的复方制剂 | |
| HK1066752B (en) | Combination of a pde inhibitor and a leukotriene receptor antagonist |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1136487 Country of ref document: HK |
|
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20090902 |
|
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1136487 Country of ref document: HK |